Use Salix Pharmaceuticals Ltd. story together with your assets to enhance returns of your portfolios as well as to check it against diversification policy that fits your risk preferences.
This story from stocks.us.reuters.com contributed to next trading day price increase. The story delta to the next closing price was 3.09% . The story delta to the current price is 15.72% .
IT Business Net - May 10, 2012
By GrabNetworks Salix Pharmaceuticals (SLXP) today had its estimates increased by Jefferies (JEF) after the company beat earnings estimates.
Junction Report - May 9, 2012
Salix Pharmaceuticals (NASDAQ: SLXP)'s stock had its ?neutral? rating restated by Zacks in a report issued on Wednesday. They currently have a $55.00 target price on the stock.
Auriga Reiterates Hold on Salix Pharmaceuticals (SLXP) - Movie News Guide (blog)
StreetInsider.com (subscription) - May 8, 2012
Jefferies analysts raised their price target on Salix Pharmaceuticals (NASDAQ: SLXP) from $54.00 to $63.00 while maintaining a BUY rating on the company.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investor monitor on a daily basis. Holding a low PE stock is less risky because. When a company's profitability fall, it is likely that earnings will also go down..In other words, if you start from a lower position your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
USA 
Equity Search
Advanced Search
Market Screener
Adviser Directory
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatility
Import Equities
Summary
Fundamentals
Technicals
Performance
Valuation
Volatility
History
News
Management
Discussion
